A wealth of data indicates that certain genetic abnormalities can target specific cytotoxic drugs and intervene at an early step as a mechanism of resistance in the treatment of non-small-cell lung cancer. Therefore prescribing
A. O'Brate, PhD
Advertisement
Articles by A. O'Brate, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
In Vivo CAR Engineering and the Next Phase of Cellular Immunotherapy
2
3 Things You Should Know About TROP2-Directed Antibody-Drug Conjugates in the Frontline Treatment of Metastatic Triple-Negative Breast Cancer
3
Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review
4
FDA Delays Decision on Subcutaneous Isatuximab in Multiple Myeloma
5